Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 8/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | PTPRB | P23467 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076560 | 0.88 | GRIN2B (0.42) | NAMPTHDAC1CTSKGRIN2BALDH1A1 | |
| SCHEMBL5075347 | 0.87 | TSHR (0.35) | NAMPTHDAC1TSHRCTSKGRIN2B | |
| SCHEMBL5073948 | 0.85 | NAMPT (0.41) | NAMPTHDAC1GRIN2BPTPRBMKNK2 | |
| SCHEMBL7375295 | 0.79 | NAMPT (0.42) | NAMPTHDAC1TSHRGRIN2BMKNK2 | |
| SCHEMBL6058817 | 0.79 | NAMPT (0.43) | NAMPTHDAC1GRIN2BPTPRBMKNK2 | |
| SCHEMBL7375395 | 0.79 | NAMPT (0.43) | NAMPTHDAC1TSHRCTSKGRIN2B | |
| SCHEMBL16296336 | 0.79 | NAMPT (0.43) | NAMPTHDAC1GRIN2BPTPRBMKNK2 | |
| SCHEMBL6058751 | 0.78 | NAMPT (0.44) | NAMPTHDAC1GRIN2BMKNK2KDM4E | |
| SCHEMBL5079027 | 0.78 | GRIN2B (0.38) | NAMPTHDAC1TSHRCTSKGRIN2B | |
| SCHEMBL7384054 | 0.77 | GRIN2B (0.42) | NAMPTHDAC1TSHRGRIN2BMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423012-B2 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7354895-B1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | LINSCHOTEN MARCEL | 2006-04-13 | — | — | US | disclosed |
| EP-1180099-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066550-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | CPN1, CPA1, DNPEP | NAMPT 824/4885HDAC1 2259/4885TSHR 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.